Awards:

  • National Institute of Health (National Heart, Lung and Blood Institute (NHLBI)):
  • Awarded 2021 Applicant Assistance Program for Small Business Innovation Research (SBIR)

  • Food and Drug Administration (FDA):
  • Nour Heart was Granted the Orphan Drug Designation (ODD) by U.S. Food and Drug Administration for its new patented drug Cyclocreatine Phosphate for the unique designation of:  prevention of ischemic injury to enhance cardiac graft recovery and survival in heart transplantation (DRU-2015-4951) 2018.

  • Women In Bio (WIB)-Founders:
  • Selected as a WIB-Entrepreneur Center: Founders Innovation Showcase Finalist to Present Nour Heart’s Products to Investors in the 2022 Bio International Convention, San Diego, California, USA. Only 10 were selected nationally.

  • National Institute of Health (National Heart, Lung and Blood Institute (NHLBI)):
  • Selected to Participate in the 2022 Catalyst Leadership Program. Only 10 were selected nationally.

  • U.S. Patent Office:
  • Inventor of eleven (11) Issued Patents Issued by the U.S. Patent Office and two pending applications, as well as the NOURIN Trademark and pending Nourexal.

Copyright @ Nour Heart 2022
Powered By : Idea World Web